Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lavoltidine
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lavoltidine is a highly potent and selective histamine H2-receptor antagonist that was developed as an oral treatment for gastroesophageal reflux disease (GERD) and peptic ulcer disease. It acts by selectively binding to and inhibiting the histamine H2 receptors on gastric parietal cells, thereby reducing gastric acid secretion. Lavoltidine is structurally related to other H2 antagonists but is distinguished by its high potency and selectivity. The drug reached phase II clinical trials but was discontinued after preclinical studies revealed that it induced gastric carcinoid tumors in rodents. It was originally developed by Glaxo Wellcome (now GlaxoSmithKline)[1][4][6].
- Brand names
- Loxtidine
- Other names
- lavoltidinaloxtidinaLavoltidine succinate
02
Targets
HRH2 (Histamine H2 Receptor)
Beyond the preview
Go deeper on lavoltidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lavoltidine.